TY - JOUR
T1 - Adverse reactions to 1% cyclopentolate eye drops in children
T2 - an analysis using logistic regression models
AU - Imai, Toshihiro
AU - Hasebe, Satoshi
AU - Furuse, Takashi
AU - Morisawa, Shin
AU - Hasebe, Kayoko
AU - Nagata, Yuka
AU - Tokutake, Tomoki
AU - Moriyama, Yumiko
N1 - Funding Information:
We would like to thank Fumio Tsuji of Santen Pharmaceutical for helpful comments.
Publisher Copyright:
© 2020 The Authors Ophthalmic and Physiological Optics © 2020 The College of Optometrists
PY - 2021/3
Y1 - 2021/3
N2 - Purpose: To determine the frequency, symptoms and risk factors for adverse reactions to two-times instillation of 1% cyclopentolate in children. Study design: Prospective, observational study. Methods: The subjects were 646 patients who underwent cycloplegic refraction with cyclopentolate (mean age; 7.0 ± 3.5 years, age range; 0–15 years). Five minutes after instillation of 0.4% oxybuprocaine hydrochloride, a 1% cyclopentolate eye drop was instilled twice, with an interval of 10 min. Fifty minutes later, two certified orthoptists evaluated adverse reactions using a questionnaire and interviewed the patients' guardians. The relationship between the adverse reaction rates and age, gender, additional instillation, complications of the central nervous system (CNS), time of day and season were analysed using binominal and polytomous logistic regression models. Results: The overall frequency of adverse reactions was 18.3% (118/646 patients). The main symptoms included conjunctival injection (10.5%, 68/646), drowsiness (6.8%, 44/646) and facial flush (2.2%, 14/646). The odds ratio (OR) of conjunctival injection increased with patient’s age (p < 0.05), in boys (p < 0.01) and in winter (p < 0.001). In contrast, the OR of drowsiness decreased with age (p < 0.001). Facial flush was observed mostly in children younger than 4 years. CNS complications were not a significant risk factor for any of the symptoms. Conclusions: Adverse reactions to 1% cyclopentolate eye drops were more frequent than previously expected, but all were mild and transient. The probability of each symptom was associated with a clear age-specific trend.
AB - Purpose: To determine the frequency, symptoms and risk factors for adverse reactions to two-times instillation of 1% cyclopentolate in children. Study design: Prospective, observational study. Methods: The subjects were 646 patients who underwent cycloplegic refraction with cyclopentolate (mean age; 7.0 ± 3.5 years, age range; 0–15 years). Five minutes after instillation of 0.4% oxybuprocaine hydrochloride, a 1% cyclopentolate eye drop was instilled twice, with an interval of 10 min. Fifty minutes later, two certified orthoptists evaluated adverse reactions using a questionnaire and interviewed the patients' guardians. The relationship between the adverse reaction rates and age, gender, additional instillation, complications of the central nervous system (CNS), time of day and season were analysed using binominal and polytomous logistic regression models. Results: The overall frequency of adverse reactions was 18.3% (118/646 patients). The main symptoms included conjunctival injection (10.5%, 68/646), drowsiness (6.8%, 44/646) and facial flush (2.2%, 14/646). The odds ratio (OR) of conjunctival injection increased with patient’s age (p < 0.05), in boys (p < 0.01) and in winter (p < 0.001). In contrast, the OR of drowsiness decreased with age (p < 0.001). Facial flush was observed mostly in children younger than 4 years. CNS complications were not a significant risk factor for any of the symptoms. Conclusions: Adverse reactions to 1% cyclopentolate eye drops were more frequent than previously expected, but all were mild and transient. The probability of each symptom was associated with a clear age-specific trend.
KW - adverse reactions
KW - amblyopia
KW - children
KW - cycloplegic refraction
KW - refractive development
KW - strabismus
UR - http://www.scopus.com/inward/record.url?scp=85097403685&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097403685&partnerID=8YFLogxK
U2 - 10.1111/opo.12773
DO - 10.1111/opo.12773
M3 - Article
C2 - 33300632
AN - SCOPUS:85097403685
SN - 0275-5408
VL - 41
SP - 424
EP - 430
JO - Ophthalmic and Physiological Optics
JF - Ophthalmic and Physiological Optics
IS - 2
ER -